ATXS — Astria Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $494.22m
- $343.01m
- 36
- 19
- 81
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 27.1 | 37.4 | 195 | 53.5 | 83 |
Operating Profit | -27.1 | -37.4 | -195 | -53.5 | -83 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.3 | -37.3 | -195 | -51.8 | -72.9 |
Net Income After Taxes | -26.3 | -37.3 | -195 | -51.8 | -72.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.3 | -37.3 | -195 | -51.8 | -72.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.3 | -37.3 | -219 | -51.8 | -72.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -14.1 | -12.2 | -24.6 | -3.55 | -2.42 |